Terns Pharma rises on early data for blood cancer drug

Terns Pharmaceuticals

03/12/2024 13:33

** Shares of Terns Pharmaceuticals  TERN.O  rise ~6% to $6.5
premarket 
    ** Co says its experimental drug to treat a type of blood
cancer showed clinically meaningful responses in patients at two
lowest dose levels
    ** The drug, TERN-701, showed no dose-limiting toxicities
across three completed dose levels, and no side-effect-related
dose reductions or discontinuations - TERN
    ** TERN plans to share additional safety and efficacy data
in late 2025
    ** The initial data was above expectations and supported
long-term use, according to BMO Capital analysts
    ** TERN-701 is being developed to treat heavily pre-treated
patients with relapsed/refractory chronic myeloid leukemia
    ** Up to last close, shares down ~5% YTD

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))